Successful organoid-mediated generation of iPSC-derived CAR-T cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35395182.
- Also identified by DOI 10.1016/j.stem.2022.03.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Artificial thymic organoids (ATOs) allow the selective differentiation of chimeric antigen receptor (CAR)-transduced human iPSCs into CAR-T cells. In this issue of Cell Stem Cell, Wang et al. now use ATOs to produce human CD19<sup>+</sup> CAR-T cells that mimic conventional CAR-T cells and effectively control the progression of human CD19<sup>+</sup> leukemia in an animal model.
Medical subject headings
- Induced Pluripotent Stem Cells
- Receptors, Chimeric Antigen
- T-Lymphocytes